chloride hydrate (S-1 108) was finally selected as the candidate for clinical evaluation.
The need still exists for the development of new orally active, semi-synthetic cephalosporins which exhibit potent, broad-spectrum, antibacterial activity. In a previous paper1* relating to the antibacterial mice. The free acid, the active form of this cephalosporin ester, showed excellent activity against both of Gram-positive and Gram-negative bacteria, but did not show satisfactory activity against Staphylococcus aureus strain. Wethen focused our attention to modification of the substituent at C-3 position to improve the antibacterial activity against S. aureus while retaining the high antibacterial activity against other Gram-positive and Gram-negative bacteria. As a result, we found that pivaloyloxymethyl 7/?-[(Z)-2-(2-aminothiazol-4-yl)-2-pentenoylamino]-3-carbamoyloxymethyl-3-cephem-4-carboxylate (22b, S-1 1 08) showed excellent oral activity and S-1006 (13b), the active form of S-1 108, showed a potent and balanced antibacterial activity against Gram-positive and Gram-negative bacteria including S. aureus. Currently, 
Chemistry
Based on the result ofantibacterial activity and oral absorbability of 3-unsubstituted cephem derivatives in the previous report, 2-(2-aminothiazol-4-yl)-3-(substituted)-2-propenoylamino side chain moieties with methyl, ethyl, cyclopentylmethyl, methylthiomethyl and benzyl were selected as the 7/?-side chains to be attached to cephems having various substituents at C-3 position. Coupling reaction of these 7/?-side chain acids 1~5 and 7^-aminocephem esters having C-3 substituents 6a~6k was carried out in the presence of an activating reagent such as methanesulfonyl chloride (MsCl) or phenylphosphoryl dichloride under Scheme 1. mild reaction conditions. Subsequent, deblocking of these esters 7~ll was effected by treatment with trifluoroacetic acid (TFA) or aluminium chloride at ambient temperature to give 12~16, respectively. POM esters of cephem acids 12b, 12c, 13a, 13b, 13d, 13g, 13j and 14b beside 15b selected from their antibacterial activity were prepared to test for oral absorbability in mice. Selective deprotection of 7b, 7c, 8a, 8b, 8d, 8g and 8j was performed by treating with TFA in dichloromethane at 0°C to give acids 17b, 17c, 18a, 18b, 18d, 18g and 18j with remaining the ter/-butoxycarbonyl group, which were reacted with POMiodide (POMI) in the presence of potassium carbonate in dimethylformamide (DMF) giving the corresponding esters 19b, 19c, 20a, 20b, 20d, 20g and 20j, respectively. These esters obtained were deblocked with TFA at room temperature to afford 21b, 21c, 22a, 22b, 22d, 22g and 22j, which were purified by column chromatography. The POMester of 15b was prepared similarly. Synthetic details for representative derivatives are described in the experimental section.
Biological Evaluation
The in vitro antibacterial activity of the new cephalosporins 12~16 against Gram-positive and Gram-negative bacteria and peak plasma levels of selected cephalosporins after oral administration (40 mg/kg) of the corresponding POMesters 21 and 22 in mice are summarized in Table 1 . For comparison, the MICvalues of cefteram (CFTM)are also listed. As shown in Table 1 , almost all compounds synthesized showed potent antibacterial activity against both Gram-positive and Gram-negative bacteria. Antibacterial activity against S. aureus including methicillin-resistant strain (SR3 1 3 1) was enhanced by introducing cyclopentylmethyl or methylthiomethyl moiety as the 7/?-side chain olefinic substituent (Rx). Compound15b showed potent and well balanced antibacterial activity, though the oral absorbability of its POM ester was poor. Introduction of heteroarylthiomethyl or 5-methyl-2//-tetrazol-2-ylmethyl group at C-3 position such as 12c, 13h~13k, 14j, 15c and 16i resulted in reduction of antibacterial activity against Gram-negative bacteria. Compounds 13d~13g with chloro, vinyl, propenyl(Z) and methoxymethyl groups at C-3 position had reduced antibacterial activity against both Gram-positive and Gram-negative bacteria. Reduced antibacterial activity against Gram-negative bacteria was observed in compounds 14a, 14b, 14j, 16b and 16i having cyclopentylmethyl and benzyl substituents as the 7/?-side chain olefinic moiety (R^. It is revealed that 12b and 13b having carbamoyloxymethyl group at C-3 position showed well balanced antibacterial activity against both Gram-positive and Gram-negative bacteria. Those acid compoundswere found not to be absorbed from small intestine in mice (data are not shown). Thus, POMesters 21b, 21c 22a, 22b, 22d, 22g and 22j of selected compounds 12b, 12c, 13a, 13b, 13d, 13g and 13j were prepared and tested for oral absorbability. As shown at the right column in Table 1 , 22g showed the highest plasma level in mice, though its acid 13g had less antibacterial activity. Compounds 21b and 22b with the carbamoyloxymethyl substituent at C-3 position showed high plasma level in mice. Thus, numbers of orally absorbable esters of the corresponding acids 12b and 13b were prepared and tested for oral absorbability (no data are shown here)2), only to find that the POMester showed the highest plasma level in mice.
As listed in Table 2 , 21b and 22b showed parallel pharmacokinetic parameters in Cmax, AUCand urinary recovery. Therapeutic efficacy of 21b and 22b was also excellent and better than that of cefteram pivoxil (CFTM-PI) against staphylococci infection3), however, the Cmax, AUCand urinary recovery of 21b and 22b were lower than those of CFTM-PI. Antibacterial activity of 13b, the active form of 22b, against S. aureus and Haemophilus influenzae was better than that of 12b. Thus, 13b was selected for further evaluation. Compound 13b is stable against /Mactamases4) and the POMester 22b showed very low nephrotoxicity5) and oral single-dose toxicity potentials6) in rabbits and rats, respectively. These data indicated that compound 22b hydrchloride hydrate designated as S-1 108, had the most preferable profile as an oral cephem in the compounds prepared and was selected as the candidate for clinical evaluation. solvents. IR spectra were taken on a Hitachi 260-10 or Jasco IR-700 spectrophotometer. *H NMRand 13C NMRspectra were recorded on a Varian EM-390 (90MHz) or a VXR200 (200MHz) spectrophotometer using TMSor sodium 3-(trimethylsilyl)-l-propane-sulfonate (in D2O) as an internal standard.
Determination of Antibacterial Activity
The in vitro antibacterial activity was given as minimuminhibitory concentration (MIC) in /ig/ml as determined by the serial agar dilution method (sensitivity test agar) after incubation at 37°C for 182 0hours with an inoculum size of one loopful of 106 CFU/ml. Sensitivity test agar containing 3% horse serum for Streptococcus pyogenes C-203 and sensitivity test agar containing 5% Fildes Enrichment for
Haemophilus influenzae SR3508 were used.
In Vivo Antibacterial Activity Test ICR female mice (age: 5weeks, weight: 19~23g) were infected intraperitoneally with bacterial suspension in 5%mucin and compoundswere administered orally 1 and.5hours after infection. ED50 values were calculated from survival ratio of mice on 7th day after infection by the probit method.
Oral Absorption Study Male ICR-strain mice aged 6 weeks weighing 24~30 g were used in groups of 5. The antibiotics were given to mice orally in a single dose of 40mg (potency)/kg or 20mg/kg for CFTM-PI. Plasma samples were collected at 0.25 and 2 hours after dosing and urine specimens were collected over a period of 2 hours after dosing. The concentrations of the active compoundswere determined by the Band Culture method7) using Escherichia coli 7431 as the test organism and trypto-soy agar as the test medium. and the reaction mixture was stirred for 4hours at -50°C, to which was added dropwise a solution of diphenylemethyl 7^-amino-3-acetoxymethyl-3-cephem-4-carboxylate (6a, 263 mg, 0.6 mmol) and TEA (180/d, 1.3mmol) in CH2C12(4ml) and the resulting mixture was stirred for 3hours at the same temperature. The reaction mixture was acidified with dil HC1and extracted with EtOAc. The extract was washed with brine and dil NaHCO3, dried and concentrated. The residue was subjected to silica gel column chromatography (eluent: EtOAc-CH2Cl2, 1 : 2) to give 7a (240mg, 68%) as a pale yellow powder. 
Compound 8b was prepared in 86% yield by coupling of 2-(2-terr-butoxycarbonylaminothiazol-4-yl)-2(Z)-pentenoic acid (2) with 6bà"TsOHin a manner similar to that used for the synthesis of 7a.
XH NMR (CDC13) 
Synthesis of Diphenylmethyl 7^-[(Z)-2-(2-rerr-Butoxycarbonylaminothiazol-4-yl)-2-pentenoylamino] -
3-(substituted)-3-cephem-4-carboxylates (8a, 8d~8k) These compoundswere synthesized similarly by reaction of 2 with the corresponding 3-substituted methyl cephem esters 6. Chemical yields, *H NMRand IR spectra are listed in Table 3 . Table 4 .
A mixture of7a (261 mg, 0.37mmol), TFA (1.0ml), anisole (0.5ml) and CH2C12 (1.5ml) was stirred at room temperature for 1 hour. After concentration, the residue was triturated with Et2O to give a light brown powder. The crude product dissolved in dil NaHCO3 was subjected to chromatography on a Diaion HP-20 (eluent: 10% MeOH). The product eluates were lyophilized to give 12a Na salt (105mg, 60.4%). 
To a solution ofA1C13 (40.2 g, 0.3 mol) in anisole (400ml) was added a solution of8b (43.4g, 0.06mol) dissolved in CH2C12(210 ml) at -30°C, and the mixture was stirred at the same temperature for 30 minutes. To the reaction mixture was added 1 n HC1 (430 ml) and triturated with EtOAc (430 ml). The aqueous layer was mixed with dil NaHCO3to adjust pH to 3.5 precipitating a light brown solid, which was filtered off and added into a mixture of NaHCO3 (24g), water (530ml), acetylacetone (7.4ml) and CH2C12 (350ml). 1 n HC1was added to the mixture to adjust pH to 7.5. The aqueous solution after separation was adjusted to pH 3.5 by addition of cone HC1 to precipitate a colorless solid. After filtration, the solid was washed 
4-carboxylates (13a, 13d~13g and 13i~13k) These compounds were synthesized by applying the method used for the synthesis of 12a. Chemical yields, *H NMRand IR spectral data are listed in Table 5 .
cephem-4-carboxylates (14a, 14b, 14j, 15b, 15c, 16b and 16i) These compoundswere synthesized by applying the method used for the synthesis of 12a. Chemical yileds, XHNMRand IR spectral data of these compounds are listed in Table 6 .
To an ice-cooled solution of8b (885mg, 1.23mmol) dissolved in anisole (3.3ml) and CH2C12 (8.3ml) was added TFA(1.9ml), and the mixture was stirred at 0°C for 2hours. After concentration, the residue was triturated with Et2O and petroleum ether to give crude 18b (675mg) as a light brown powder.
A suspension of 18b (3.45g, 6mmol), K2CO3 (1.65g, 7.2mmol) and DMF (35ml) was treated with POMI(1.15ml, 6.8mmol) at -40°C for 1.5hours. The reaction mixture was mixed with 10% H3PO4and extracted with EtOAc. The extract was washed with brine and water, dried and concentrated. The residue b IR spectral data of free acids are listed. N, Nujol; K, KBr. 
